"Neoplasm, Residual" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Remnant of a tumor or cancer after primary, potentially curative therapy.
| Descriptor ID |
D018365
|
| MeSH Number(s) |
C04.697.700 C23.550.727.700
|
| Concept/Terms |
Neoplasm, Residual- Neoplasm, Residual
- Residual Neoplasms
- Residual Neoplasm
- Minimal Residual Disease
- Minimal Disease, Residual
- Residual Minimal Disease
- Residual Minimal Diseases
- Residual Disease, Minimal
- Minimal Residual Diseases
Residual Tumor- Residual Tumor
- Residual Tumors
- Residual Tumour
- Residual Tumours
- Tumour, Residual
|
Below are MeSH descriptors whose meaning is more general than "Neoplasm, Residual".
Below are MeSH descriptors whose meaning is more specific than "Neoplasm, Residual".
This graph shows the total number of publications written about "Neoplasm, Residual" by people in this website by year, and whether "Neoplasm, Residual" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 4 | 4 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 0 | 1 | 1 |
| 2003 | 2 | 1 | 3 |
| 2004 | 0 | 2 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 3 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 8 | 8 |
| 2013 | 1 | 4 | 5 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 4 | 5 |
| 2016 | 3 | 3 | 6 |
| 2017 | 3 | 5 | 8 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 5 | 9 |
| 2020 | 4 | 1 | 5 |
| 2021 | 3 | 5 | 8 |
| 2022 | 1 | 9 | 10 |
| 2023 | 0 | 5 | 5 |
| 2024 | 3 | 5 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neoplasm, Residual" by people in Profiles.
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
-
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. Radiology. 2024 09; 312(3):e232748.
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 Jul 25; 391(4):320-333.
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
The association of histopathologic features after neoadjuvant chemo-immunotherapy with clinical outcome: Sub-analyses from the randomized double-blinded, placebo-controlled, Phase III IMagyn050/GOG3015/ENGOT-ov39 study. Gynecol Oncol. 2024 07; 186:17-25.
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.
-
Measurable Residual Disease and Decision-Making in Multiple Myeloma. Hematol Oncol Clin North Am. 2024 04; 38(2):477-495.
-
MRD-guided treatment cessation in multiple myeloma. Lancet Haematol. 2023 11; 10(11):e867-e868.
-
Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer. J Clin Oncol. 2023 Dec 01; 41(34):5296-5305.